Skip to content
Sanofi
-
FDA approves Sanofi’s Qfitlia for Hemophilia A and B
Unlike traditional treatments that replace missing clotting factors, Qfitlia functions by reducing levels of antithrombin, a protein that hinders blood clotting.
-
Sanofi acquires Dren Bio’s DR-0201 in US$1.9B immunology deal
DR-0201 is a bispecific myeloid cell engager (MCE) designed to induce deep B-cell depletion via targeted phagocytosis, offering a potential breakthrough in treating refractory B-cell-mediated autoimmune diseases, including lupus.
-
-
-
-
-
-
-
-
